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Porcine intestinal gastrin-releasing peptide (GRP) has been demonstrated to be structurally identical to the 
previously characterized gastric GRP. Ion-exchange and high-performance liquid chromatography of 
porcine intestinal extracts have identified two variant GRP forms. Studies on one of these variant forms 
suggest that a ,&aspartyl shift has occurred in the Asn-His structure of GRP; such a modification in an 
Asn-His structure occurring in a natural peptide or protein has not been previously reported. This variant 
GRP, although retaining bioactivity, appears to have reduced potency in elevating canine plasma gastrin 
levels. 
Gastrin-releasing peptide (GRP) Bombesin Gostrin release HPLC 
Ion-exchange chromatography fl-Aspartyl shtft 
1. INTRODUCTION 2. EXPERIMENTAL 
Gastrin-releasing peptide (GRP) was originally 
isolated from porcine upper gastric tissue [1] and 
its structure was found to contain a C-terminal 
region with striking homology towards bombesin 
[2]. During purification of a similar peptide from 
porcine intestinal extracts [1,3], carboxy- 
methylcellulose (CMC) chromatography revealed 
the presence of a gall bladder contracting factor in 
a fraction which elutes before the identified form 
of GRP. Considering the numerous reports of 
heterogeneity of peptides in gastrointestinal tissue 
[4-91 and of multiple forms of bombesin-like im- 
munoreactivity in avian and mammalian 
gastrointestinal tissue [lo-121, this early eluting 
fraction was thought to contain a variant form(s) 
of GRP. Here, the isolation and chemical 
characterization of one such GRP variant is 
described, a second variant form identified and the 
previously identified form of porcine intestinal 
GRP demonstrated to have the same amino acid 
sequence as the gastric peptide. 
2.1. Purification procedures 
Chemicals, materials and details of 
chromatographic procedures have been described 
[ 1,131. GRP-like bioactivity was determined by an 
in vivo guinea pig gall bladder contracting assay 
[ 141 and the criterion for an increase in purity dur- 
ing isolation of the GRP and its variants was an in- 
crease in potency of the gall bladder contracting 
activity. Fractions generated by reverse-phase high 
performance liquid chromatography (HPLC) were 
assayed [15,16] for bombesin-like immunoreactivi- 
ty (using an antiserum generously supplied by Drs 
M.A. Ghatei and S.R. Bloom). For purification, 
the starting material was the post-secretin fraction 
obtained during purification of porcine secretin 
[ 171. This material was dissolved in a 25.5 mM 
sodium phosphate @H 6.4) buffer, applied ‘to a 
CMC column (5 x 19 cm) and eluted with a linear 
gradient from O-O.3 M NaCl in the same buffer. 
Two bioactive fractions (variant and GRP frac- 
tion, fig.1) in distinctly separated peaks were col- 
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Fig. 1. CMC chromatography of 3.79 g post-secretin fraction [ 171. Elution with a linear gradient of O-O.3 M NaCl in 
0.0225 M sodium phosphate buffer @H 6.4); column, 5 x 19 cm; fraction vol., 14 ml. The elution pattern was 
monitored by measuring absorbancy at 275 mn. Fractions containing GRP-like activity were pooled as indicated by the 
bars. After recovery, the peptide material in the GRP and variant fractions weighed 363 mg and 268 mg, respectively. 
lected and desalted on a Sephadex G-25 column 
eluted with 0.2 M acetic acid. 
Pooled fractions, from such initial CMC 
chromatographies, containing GRP (1.1 g) and 
proposed variant GRP (1.51 g) were dissolved in 
0.02 M ammonium bicarbonate (pH 8.0) and 
separately subjected to further CMC 
chromatographies. The GRP containing sample 
was applied to a CMC column (5 x 19 cm), eluted 
with 600 ml 0.02 M ammonium bicarbonate and 
then with 0.05 M ammonium bicarbonate during 
which the GRP-like bioactivity eluted between 
2890-3180 ml. The proposed variant GRP con- 
taining sample was applied to a CMC column (5 x 
19 cm) and during elution with 0.02 M ammonium 
bicarbonate, GRP-like bioactivity emerged be- 
tween 3865-4550 ml. After recovery by lyophiliza- 
tion, the peptide material in the GRP and pro- 
posed variant GRP containing fractions weighed 
23.1 mg and 34.7 mg, respectively. Final purifica- 
tion was by reverse-phase HPLC using a Waters 
instrument consisting of a micro-Bondapack Cl8 
column (7.8 x 300 mm), a U6K injector, two 
M 6000 A pumps, a 660 solvent programmer and 
a 450 detector. Peptide peaks were detected by 
monitoring absorbancy at 215 nm, solvent systems 
were 0.1% trifluoroacetic acid in water (A) and 
acetonitrile (B), respectively and the flow rate was 
2 ml/mm. The GRP fraction was purified by a 
linear gradient from 25-40% B solvent in 1 h, the 
variant fraction was purified by an isocratic elu- 
tion with 25% B for 24 min followed by a linear 
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gradient from 25-40% B solvent over 1.5 h. Tryp- 
tic fragments were purified by linear gradient elu- 
tion from O-50% B solvent in 45 min. 
The HPLC purified preparations were 
bioassayed for gastrin-releasing properties in dogs 
as in [1,13]. Plasma gastrin levels were estimated 
by radioimmunoassay [18] using the antiserum 
2604 (a generous gift of Dr Jens Rehfeld). 
2.2. Structural analysis 
C-Terminal amide structures were determined 
by enzymatic hydrolysis, dansylation, and subse- 
quent identification of amides [19]. N-Terminal 
amino acids were determined by the dansyl techni- 
que and identified on polyamide sheets using 4 
chromatographic systems [20]. Peptides were 
digested with trypsin [20] and the resulting 
fragments were separated by reverse-phase HPLC. 
Amino acid analyses were performed on a 
Beckman 121M analyzer after hydrolysis at 110°C 
for 24 h in evacuated tubes containing 6 M HCl. 
Liquid-phase sequencer degradation in a Beckman 
890D instrument using a 0.1 M Quadrol peptide 
program was performed in the presence of 
polybrene added together with glycine and degrad- 
ed for 2 cycles before peptide application [21]. 
Phenylthiohydantoin amino acids were determined 
on a Hewlett-Packard 1084B HPLC instrument us- 
ing an acetonitrile gradient system [22]. Samples 
were also analyzed by silica gel thin-layer 
chromatography with fluorescent indicator and 
subsequent staining with collidine-ninhydrin [23]. 
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Manual sequence analysis was by the 
dimethylaminoazobenzene isothiocyanate techni- 
que [24] using by-products as an aid in identifica- 
tion [25]. 
3. RESULTS 
with a synthetic replicate of GRP. Final yields of 
V-l and V-2 were 0.92 and 0.723 mg respectively, 
and both had different HPLC retention times from 
that of GRP (fig.3). Silica gel thin-layer 
chromatographies of GRP and V-l preparations 
were consistent with both having a high degree of 
3.1. Isolation Table 1 
Reverse phase HPLC of the GRP fraction 
demonstrated one major area of immunoreactivity 
(fig.2) while that of the variant fraction 
demonstrated two distinct peaks of immunoreac- 
tivity (fig.3) which were designated V-l and V-2. 
The GRP preparation (1.41 mg final yield), as with 
previous preparations (26), co-eluted on HPLC 
Amino acid compositions of the tryptic fragments of 
GRP and V-l 
Residue GRP V-l 
Tl T2 T3 Tla T2a T3a 
Asx 
Thr 
Ser 
GlX 
Pro 
Gly 
Ala 
Val 
Met 
Ile 
Leu 
TYr 
Phe 
Trp 
LYS 
His 
Arg 
1.0 (1) 1.0 
1.0 (1) 0.9 (1) 
1.0 (1) 0.2 (0) 0.9 (1) 0.3 
0.2 (0) 
1.0 (1) 1.1 (1) 1.1 (1) 1.2 (1) 
3.0 (3) 2.1 (2) 3.0 (3) 2.0 
2.0 (2) 1.1 (1) 0.4 (0) 2.0 (2) 1.0 
3.1 (3) 1.0 (1) 2.9 (3) 1.0 
0.8 (1) 0.8 (1) 1.0 (1) 0.6 
C 
E 
c 
w 
s 
w c 
f 
2 
Fig.2. Reverse-phase HPLC of 1 mg GRP fraction from 
CMC chromatographies. The active material was 
collected as shown by the bar. 
0.9 (1) 0.9 (1) 0.9 (1) 0.8 
0.9 (1) 0.9 (1) 
- (1) - 
1.2 (1) 1.0 (1) 
1.8 (2) 1.9 
1.0 (1) 1.0 (1) 
The first values show molar ratios from acid 
hydrolysates (values below 0.1 omitted), values in 
parentheses the sum from sequence analysis 
Fig.3. Reverse-phase HPLC of 1 mg variant fraction from CMC chromatographies. Activity was found in two peaks, 
designated V-l and V-2, which were collected as shown by the bars. (1) Retention time of GRP. 
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Fig.4. Reverse-phase HPLC of 6 pg tryptic digests of GRP (4a) and V-l (4b), and a mixture of 3.5 fig of each of the 
tryptic digests of GRP and V-l (4~). 
homogeneity. The mobilities of GRP and its syn- 
thetic replicate were identical (RF 0.59) while that 
of V-l was slightly less (RF 0.57). Thin-layer 
chromatography of preparation V-2 demonstrated 
the presence of contaminating peptides and hence, 
this fraction has not been fully characterized. 
3.2. End groups, tryptic fragments 
Analysis by the dansyl method revealed that 
both GRP and V-l had an N-terminal alanine 
residue and that lysine and tyrosine were present in 
the peptides (as cu-dansyl-alanine, -dansyl-lysine 
and O-dansyl-tyrosine were demonstrated with vir- 
tually no contamination by other derivatives). 
Analysis of the V-2 preparation demonstrated the 
presence of the same main derivatives, suggesting 
that the N-terminus of V-2 is alanine, but con- 
tamination with other derivatives was present. C- 
terminal amide analysis [ 1,191, demonstrated that 
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all 3 preparations contained the C-terminal leucyl- 
methionine amide structure. 
N-Terminal analysis of the peptide fragments 
(nomenclature as in fig.4) isolated from tryptic 
digests of GRP and V-l suggested that Tl and Tla 
(both having N-terminal methionine), T2 and T2a 
(both having N-terminal alanine), and T3 and T3a 
(both having N-terminal glycine) were, respective- 
ly, the middle, N-terminal and C-terminal 
fragments of the parent peptides. The amino acid 
compositions of the corresponding GRP and V-l 
tryptic fragments were identical (table 1) and in 
agreement with the compositions predicted from 
the previous sequence analysis of the gastric GRP 
[l]. Reverse-phase HPLC of mixtures of the cor- 
responding GRP and V-l tryptic fragments (fig.4) 
showed co-elution of Tl and Tla and of T2 and 
T2a but not of the C-terminal decapeptides T3 and 
T3a. As T3 and T3a have identical compositions 
FEBS LETTERS June 1983 Volume 156, number 2 
a) GRP 
1 5 10 15 
Ala -Pro -Val- Ser-Val- Gly- Gly- Gly-Thr-Val -Leu -Ala-Lys-Met-Tyr- Pro- Arg 
HT_ q j& HT HT HT HT HT HT 
HT H‘T ttf 
3 HT 4 HT H 
/1:7.~ ,,7;'1 
20 25 
Gly- Asn- His-Trp- Ala-Val-Gly-His-Leu-Met-NH2 
H H H HT H H H 
77 77 7 7 7 
T3 ~ 
b) Vl 
1 5 10 15 
Ala -Pro-Val-Ser-Val-Gly-Gly-Gly-Thr- Val- Leu-Ala- Lys-Met-Tyr-Pro- Arg 
HT H HT HT HT HT HT HT HT HT HT HT HT HT HT H H 
77777777777777777 
T2a 1 I--- T1a ------I 
20 25 
;;Y-(A sn, His, Trp, Ala, Val, Gly, His,)-Leu-Met- NH2 
fL----- T3a 
\K-- 
I 
Fig.5. Summaries of the sequence analysis of 25 run01 GRP (repetitive yieid 95%) and V-l (repetitive yield %BJo) are 
given in 5s and Jb, respectively. The positions of the 3 tryptic fragments in GRP (T,, T2, Ta) and V-l (Tta, Tza, T3,,) 
are also given. Residues identified by sequencer degradation are given by - ; HPLC PTH-analysis by H; TLC PTH- 
analysis by T; and residues identified by C-terminal amide analysis by -. 
and N- and C-termini, the different chromatogra- 
phic behaviour must be explained by an internal 
rearrangement. 
3.3. Sequence determination 
Liquid phase sequencer degradation of GRP 
identified residues up to position 24. With the 
histidine residue in position 25 assigned from the 
amino acid composition of T3, the resulting struc- 
ture (fig.Sa) is identical to that determined for the 
gastric peptide [I]. Liquid-phase sequence 
degradation demonstrated that V-l had structural 
identity with GRP up to position 18 (fig.5b) but 
degradation of the peptide abruptly halted after 
this position. Manual sequence analysis of the C- 
terminal tryptic fragment of GRP con~rmed the 
sequencer degradation results but a similar manual 
sequence analysis of the C-terminal tryptic frag- 
ment of V-l failed after identification of the initial 
glycine residue (position 18 in the intact molecule, 
f”rg.Ja,b). Hence, the demonstrated differences 
between the GRP and V-l appear to involve the 
asparagine residue in position 19 (Asn-19). A 
possible explanation for the observed phenomena 
is that a rearrangement has occurred in V-l 
whereby the peptide chain after Asn-19 has 
migrated from the a-carboxyl of Asn-19 to the fl- 
carboxyl. Such a&aspartyl shift would explain the 
block in the Edman degradation at residue 19 
[27,28] and result in the formation of a now free 
353 
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Fig.6. Plasma immunoreactive gastrin levels (pg/ml) before and after intravenous bolus injection (t) of 300 pmol/kg 
of GRP and V-l into 3 dogs. 
carboxyl group which may result in the different 
ion-exchange chromatographic properties of GRP 
and V-l. The differences observed during the 
purifications and sequence degradations and the 
unchanged total amino acid compositions of the 
two peptides are compatible with this proposed @- 
aspartyl shift. 
3.4. Biological activity 
V-l has gastrin-releasing properties but appears 
to be less potent than GRP (fig.6). Although com- 
plete dose-response studies are necessary to deter- 
354 
mine the precise degree of relative potencies of V-l 
and GRP, the suggested @-asparty shift is not 
associated with complete inactivation. 
4. DISCUSSION 
This study confirms the original structure pro- 
posed for the porcine GRP by demonstrating iden- 
tity between the intestinal and gastric peptides. A 
recent study [29] reports that a canine intestinal 
bombesin-like peptide is identical to the porcine 
GRP except for 4 residue differences occurring in 
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the N-terminal 12 residues. Hence, an originally 
proposed His/Gin change between porcine GRP 
and bombesin occurring at the eighth position 
from their C-termini [l], is also present in related 
peptides isolated from the chicken proventriculus 
[30] and the canine intestine [29]. 
The differences between GRP and V-l observed 
during reverse-phase HPLC, ion-exchange 
chromatography and sequence degradations are 
consistent with a fl-aspartyl shift occurring in the 
Asn-His (position 19-20) structure. ,&Aspartyl 
shifts have been observed during analytical studies 
on naturally occurring proteins [27,28,31], and the 
Asp-Gly structure in the peptides secretin [32,33] 
and PHI [34] have been noted to undergo such an 
internal rearrangement. Studies on synthetic pep- 
tides suggest hat a ,&aspartyl shift may occur via 
formation of a cyclic imide which, on opening, 
partly gives rise to the &aspartyl peptide [35,36]. 
This rearrangement occurs particularly easily if an 
asparaginyl residue is linked to a subsequent 
glycine, serine, or threonine residue [36] and the 
conversion of asparaginylglycine into the &isomer 
occurs more rapidly than a similar conversion of 
aspartylglycine [37]. Other than the reported 
presence of a &aspartylhistidine dipeptide in 
human urine [38], there appears to have been no 
previous demonstration of the occurrence of a & 
aspartyl shift in the Asn-His structure in a natural 
protein or peptide. However, a study using the syn- 
thetic peptide N-benzyloxycarbonyl-P- 
benzylaspartyl histidine methyl ester has 
demonstrated that such a ,&aspartyl shift occurs 
readily, even at -25”C, on treatment of the syn- 
thetic peptide with anhydrous HF and anisole and 
subsequently with 1% ammonium bicarbonate 
[39]. During the purification of GRP [l, 131, the 
peptide extracts are briefly exposed to 0.2 M HCI 
and subsequently to ammonium bicarbonate; these 
procedures may provide conditions under which 
such a fi-aspartyl shift could occur in GRP. 
Heterogeneity of bioactive gastrointestinal and 
neuropeptides has usually been described in terms 
of differences in molecular size, with either precur- 
sors or fragments of a parent molecule being 
recognized. Such precursor or fragment molecules 
may exhibit heterogeneity on ion-exchange 
chromatography due to deletions or additions of 
charged residues. Heterogeneity of a peptide entity 
on ion-exchange chromatography in the absence of 
demonstrable size heterogeneity, would suggest 
modification or substitution of an internal 
residue(s); one such possible alteration is the & 
aspartyl shift which, if involving a residue such as 
asparaginyl, might result in a less positively charg- 
ed peptide. The GRP variant, V-l, very likely 
results from a&aspartyl shift and it is possible that 
some of the previous ion-exchange heterogeneity 
reported for canine intestinal bombesin-like pep- 
tides [ 1 l] may be similarly explained. Of practical 
import, V-l was found to be less potent than GRP. 
Consequently, GRP preparations which show less 
than the expected potency [40] should probably be 
investigated (by ion-exchange chromatography) 
for the presence of this variant form. 
Finally, the present study also identifies a second 
variant of GRP, V-2, which has not yet been ob- 
tained completely free of contaminants. Structural 
studies on V-2 may provide additional insights into 
the heterogeneity of these bioactive 
gastrointestinal tract peptides. 
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